The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

(2016) Dimitrios P. Kontoyiannis et al.   BMC INFECTIOUS DISEASES

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

The VITAL study: case control studies are hypothesis-generating – Authors' reply

(2016) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

(2016) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

Mucormycosis in Iran: a systematic review

(2016) Afsane Vaezi et al.   MYCOSES

Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis

(2016) Laura L. Kovanda et al.   Expert Review of Clinical Pharmacology

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis

(2015) F. Lanternier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data

(2014) Marya D Zilberberg et al.   BMC INFECTIOUS DISEASES

A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients

(2014) M. Mansour Ceesay et al.   BRITISH JOURNAL OF HAEMATOLOGY

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

(2014) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

Our 2014 approach to mucormycosis

(2014) Daniela Tacke et al.   MYCOSES

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology and Clinical Manifestations of Mucormycosis

(2012) George Petrikkos et al.   CLINICAL INFECTIOUS DISEASES

A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)

(2012) F. Lanternier et al.   CLINICAL INFECTIOUS DISEASES

Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)

(2012) A. Xhaard et al.   CLINICAL MICROBIOLOGY AND INFECTION

Mucormycosis treated with posaconazole: review of 96 case reports

(2012) Joerg J. Vehreschild et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

(2011) A. Skiada et al.   CLINICAL MICROBIOLOGY AND INFECTION

Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases

(2010) Shmuel Shoham et al.   MEDICAL MYCOLOGY

Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis

(2008) Georgios Chamilos et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

(2008) Ashraf S. Ibrahim et al.   MEDICAL MYCOLOGY